Wen-Ming Chen

9.5k total citations
323 papers, 4.4k citations indexed

About

Wen-Ming Chen is a scholar working on Molecular Biology, Ecology and Hematology. According to data from OpenAlex, Wen-Ming Chen has authored 323 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 235 papers in Molecular Biology, 100 papers in Ecology and 89 papers in Hematology. Recurrent topics in Wen-Ming Chen's work include Genomics and Phylogenetic Studies (141 papers), Microbial Community Ecology and Physiology (89 papers) and Multiple Myeloma Research and Treatments (85 papers). Wen-Ming Chen is often cited by papers focused on Genomics and Phylogenetic Studies (141 papers), Microbial Community Ecology and Physiology (89 papers) and Multiple Myeloma Research and Treatments (85 papers). Wen-Ming Chen collaborates with scholars based in Taiwan, China and South Korea. Wen-Ming Chen's co-authors include Shih‐Yi Sheu, Chiu‐Chung Young, A. B. Arun, Jih‐Terng Wang, Peter Vandamme, Lionel Moulin, Cyril Bontemps, Catherine Boivin-Masson, Gilles Béna and Duan Weng and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Wen-Ming Chen

302 papers receiving 4.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wen-Ming Chen Taiwan 32 2.4k 1.2k 674 468 432 323 4.4k
Helmut König Germany 46 2.9k 1.2× 1.2k 1.0× 909 1.3× 705 1.5× 418 1.0× 235 6.6k
Robert J. Maier United States 48 2.2k 0.9× 470 0.4× 2.0k 3.0× 88 0.2× 262 0.6× 220 7.2k
Masaaki Morikawa Japan 45 3.5k 1.5× 1.2k 0.9× 855 1.3× 151 0.3× 182 0.4× 220 7.3k
Ben Herbert Australia 42 2.5k 1.1× 308 0.2× 386 0.6× 69 0.1× 167 0.4× 108 5.8k
Xi‐Ying Zhang China 33 2.5k 1.1× 1.5k 1.2× 586 0.9× 106 0.2× 82 0.2× 182 4.3k
Jeffrey A. Cole United Kingdom 48 2.9k 1.2× 956 0.8× 447 0.7× 39 0.1× 97 0.2× 139 5.9k
Nobuyuki Fujita Japan 51 5.7k 2.4× 1.3k 1.1× 519 0.8× 52 0.1× 605 1.4× 394 10.2k
Guanjun Chen China 33 2.0k 0.8× 1.0k 0.8× 501 0.7× 52 0.1× 73 0.2× 227 4.2k
Wataru Hashimoto Japan 44 2.7k 1.1× 345 0.3× 1.3k 1.9× 92 0.2× 433 1.0× 229 6.3k
Tae-Kwang Oh South Korea 37 3.7k 1.6× 2.1k 1.7× 982 1.5× 152 0.3× 267 0.6× 141 5.0k

Countries citing papers authored by Wen-Ming Chen

Since Specialization
Citations

This map shows the geographic impact of Wen-Ming Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wen-Ming Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wen-Ming Chen more than expected).

Fields of papers citing papers by Wen-Ming Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wen-Ming Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wen-Ming Chen. The network helps show where Wen-Ming Chen may publish in the future.

Co-authorship network of co-authors of Wen-Ming Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Wen-Ming Chen. A scholar is included among the top collaborators of Wen-Ming Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wen-Ming Chen. Wen-Ming Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lasica, Masa, Sikander Ailawadhi, Chengcheng Fu, et al.. (2024). Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology. 42(16_suppl). 7078–7078. 1 indexed citations
2.
Jian, Yuan, Yanru Zhang, Yin Wu, et al.. (2024). Paired comparisons of venetoclax concentration in cerebrospinal fluid, bone marrow, and plasma in acute leukemia patients. Clinical and Translational Science. 17(9). e70006–e70006. 1 indexed citations
3.
4.
Zhou, Huixing, Huijuan Wang, Yun Leng, et al.. (2023). Characteristics and Risk Factors of Ultra-High-Risk Patients with Newly Diagnosed Multiple Myeloma. Journal of Personalized Medicine. 13(4). 666–666. 1 indexed citations
5.
Wang, Xiaoying, Qianqian Yao, Wen-Ming Chen, et al.. (2023). Correlation Analysis between Residual Pain after Vertebral Augmentation and the Diffusion Distribution of Bone Cement: A Retrospective Cohort Study. Pain Research and Management. 2023. 1–10. 6 indexed citations
6.
Fu, Chengcheng, et al.. (2022). The Clinical Characteristics of Immunoglobulin Light Chain Amyloidosis in the Chinese Population: A Systematic Scoping Review. SHILAP Revista de lepidopterología. 4(1). 12–25. 1 indexed citations
7.
Wang, Xiaojuan, et al.. (2021). Clinical Characteristics and Risk Factors for Pleural Effusion in Patients with Multiple Myeloma. International Journal of General Medicine. Volume 14. 649–657. 3 indexed citations
8.
Raittz, Roberto Tadeu, Marta Maluk, Marcelo Bueno Batista, et al.. (2021). Comparative Genomics Provides Insights into the Taxonomy of Azoarcus and Reveals Separate Origins of Nif Genes in the Proposed Azoarcus and Aromatoleum Genera. Genes. 12(1). 71–71. 18 indexed citations
9.
Wang, Huijuan, Yin Wu, Yun Leng, et al.. (2020). Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients. Leukemia & lymphoma. 62(4). 883–890. 6 indexed citations
10.
Gao, Wen, Yuan Jian, Juan Du, et al.. (2020). Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China. Cancer Medicine. 9(21). 7819–7829. 11 indexed citations
11.
Zhang, Zhiyao, et al.. (2019). Potential Relationship between Clinical Significance and Serum Exosomal miRNAs in Patients with Multiple Myeloma. BioMed Research International. 2019. 1–8. 23 indexed citations
12.
Zhang, Zhiyao, et al.. (2019). Serum exosomal microRNAs as novel biomarkers for multiple myeloma. Hematological Oncology. 37(4). 409–417. 41 indexed citations
13.
Chen, Wen-Ming, Yin Wu, Jianyong Li, et al.. (2019). 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China. The Oncologist. 24(11). e1132–e1140. 20 indexed citations
14.
Chen, Wen-Ming, Xiaomeng Wang, Bin Chen, et al.. (2016). [Spatial distribution characteristics analysis on multidrug-resistant tuberculosis cases in Zhejiang province, 2010-2012].. PubMed. 37(6). 831–5. 3 indexed citations
15.
16.
17.
18.
19.
Wang, Jing & Wen-Ming Chen. (2009). A case report of Castleman's disease transformed into Hodgkin's lymphoma with literature review. 18(11). 684–686. 1 indexed citations
20.
Chen, Wen-Ming, Chi‐Rei Yang, Chen‐Li Cheng, Yen‐Chuan Ou, & Hao‐Chung Ho. (2003). Vesical Endometriosis: A Case Report. 14(4). 183–186. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Helmut König Breakdown of academic impact, for papers by Robert J. Maier Breakdown of academic impact, for papers by Masaaki Morikawa Breakdown of academic impact, for papers by Ben Herbert Breakdown of academic impact, for papers by Xi‐Ying Zhang Breakdown of academic impact, for papers by Jeffrey A. Cole Breakdown of academic impact, for papers by Nobuyuki Fujita Breakdown of academic impact, for papers by Guanjun Chen Breakdown of academic impact, for papers by Wataru Hashimoto Breakdown of academic impact, for papers by Tae-Kwang Oh
Rankless by CCL
2026